Targeted Therapies and Drug Delivery for Neurodegenerative Diseases
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Targeting and Design".
Deadline for manuscript submissions: 28 February 2026 | Viewed by 89
Special Issue Editors
Interests: neurodegenerative diseases; pharmacology; drug discovery; drug repurposing; neuroinflammation
Special Issues, Collections and Topics in MDPI journals
Interests: neurodegenerative disease; epilepsy; pharmacology; neuroinflammation
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
The treatment of neurodegenerative diseases faces two major hurdles: the complexity of disease mechanisms and the challenge of efficiently delivering therapeutics to the central nervous system. Disorders such as Alzheimer’s Disease (AD), Parkinson’s Disease (PD), Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and epilepsy involve intricate pathological cascades, including protein misfolding, neuroinflammation, oxidative stress, and synaptic dysfunction. Moreover, the blood–brain barrier (BBB) severely limits the passage of most pharmacological agents, hindering the efficacy of potential treatments.
Recent breakthroughs in targeted therapies and advanced drug delivery systems are reshaping the therapeutic landscape, offering unprecedented precision in modulating pathological processes while overcoming biological barriers. Nanoparticle-based carriers, ligand-directed approaches, exosome-mediated delivery, and biomimetic platforms have shown great promise in enhancing drug bioavailability and selectivity. In parallel, gene- and peptide-based therapeutics are emerging as powerful tools to correct disease mechanisms at the molecular level, paving the way for disease-modifying treatments.
This Special Issue seeks cutting-edge contributions on innovative strategies that push the boundaries of neurodegenerative disease treatment. We invite original research and review articles focusing on novel drug formulations, advanced delivery platforms, and BBB-targeting mechanisms and translational studies bridging preclinical and clinical applications. By fostering interdisciplinary collaboration and highlighting the latest advancements in the field, this issue aims to accelerate the development of transformative therapies and improve patient outcomes in the fight against neurodegeneration.
We look forward to receiving your contributions.
Dr. Ramona Meanti
Dr. Chiara Lucchi
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- targeted drug delivery
- blood–brain barrier
- neurodegenerative disease treatment
- precision medicine
- neuroscience
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
